Climacteric Syndrome In Women Research Articles

Prediction of severe post-castration syndrome in women after surgical menopause

Objectives: prediction of severe post-castration syndrome (PCS) in women after surgical menopause.Materials and methods. The study included 67 surgically menopausal women aged 45–55 years who underwent surgical hysterectomy with or without appendages (the main group) and 30 naturally menopausal women (the comparison group). The method of constructing and analyzing multifactorial mathematical models was used to identify risk factors associated with the development of severe PCS in women after surgical menopause and assess its impact on the severity of PCS. 12 clinical and morphological factors were considered in the analysis. The severity of the PCS in women after surgical menopause was evaluated one month after surgery and symptoms of climacteric syndrome in women with natural menopause were assessed according to the modified Kupperman index.Results. Surgical menopause significantly increases the risk of severe PCS in comparison with natural menopause, when climacteric syndrome develops (p < 0.001). The risk of severe PCS increases with the removal of the uterine appendages, inflammatory changes in the uterine appendages, the ovarian cyst (p < 0.001), and uterine fibroids (p = 0.04). Three factor signs remain after selecting a set of independent signs in a multifactorial model for predicting the risk of severe PCS: removal of the uterine appendages (p < 0.001), inflammatory changes in the uterine appendages (p = 0.006), ovarian cyst (p = 0.082). Based on these factor signs, we can accurately predict the risk of severe PCS (AUC = 0.951, 95% CI 0.89–0.98).Conclusions. Women with surgical menopause after the uterine appendages removal, with inflammatory changes in the uterine appendages, and ovarian cysts are at risk for the development of severe PCS and therefore it is advisable for them to include in the complex treatment of PCS medicines which reduce inflammatory changes in the uterine appendages and restore immunological reactivity.

DT56a in treatment of climacteric syndrome in the Central European population sample.

The aim of this study was to assess the possibility of using the DT56a for the therapy of acute climacteric syndrome in women in Slovakia and the Czech Republic. Prospective interventional unblinded study. A sample of 453 women with symptoms of acute climacteric syndrome took 644 mg of soybeans´ phyotestrogenes DT56a in the period of 4 weeks. In course of the therapy, the total number of hot flushes decreased by 48 %, and the intensity decreased by 35 % (p < 0.01). In 85 % of women, the quantity or intensity of hot flushes decreased. Sleep quality increased in 65 % of women, headaches improved or significantly improved in 51 % of women, muscle aches and joint pains decreased by 40 %. Life quality improved in 72 % of women. DT56a is a possible alternative for the treatment of acute climacteric syndrome. In the Central European population, the efficacy of a daily dose of 644 mg corresponds with the effects observed in the Mediterranean population (Tab. 2, Fig. 3, Ref. 21). Text in PDF www.elis.skKEY WORDS: DT56a, climacteric syndrome, menopause, non-hormonal treatment.

Indicators of the immune system after correction of climacteric syndrome in women with uterine leiomyoma and endometrial hyperplasia

Indicators of the immune system after correction of climacteric syndrome in women with uterine leiomyoma and endometrial hyperplasia

Features of climacteric syndrome in women with endometriosis

Share of patients with endometriosis among women of perimenopausal age is about 50% thus the problem of climacteric syndrome (СS) is extremely actual. The processes of maladaptation of neurocircular regulation are observed at reproductive age especially in this category of women. Considering the above-mentioned, research of the CS`s run of the disease; against the background of endometriosis and the choice of the correct tactics of the management of such patients becomes extremally crucial. The article deals with issues of identification of the frequency of CS in patients with endometriosis and features of development of the disease.The exanimated group of patients consisted of 1055 women of late reproductive and perimenopausal women (from 39 to 55 years), 520 of them had diagnosis endometriosis (control group) and 535 without endometriosis(comparison group). At the next stage were examined 323 women: 170 with endometriosis and 153 without this pathology, which were divided into groups depending on the presence or absence of CS’s symptoms. Also were searched four electronic databases.During the analysis of groups of patients were studied, it was found that the incidence of CS in group of women with endometriosis was significantly higher (p &lt;0.05) than in the comparison group, with manifestations of the CS earlier than in women of the general population. Were found the following risk factors for the development of a climacteric syndrome against the backdrop of endometriosis: psychical and intellectual overload, the presence of chronic stressful situations, adverse environmental conditions of living and harmful factors of labor, menstrual disorders in reproductive age, especially abnormal uterine bleeding, premenstrual syndrome, three or more abortions, the absence of birth in the history, the presence of postoperative surgical interventions in reproductive age, as well as significant somatic burdened anamnesis.Given the results of the study, it can be argued that the CS is the psycho-emotional and vegetative crisis which in combination with severe premorbid background – endometriosis, significantly increases the impact on the general condition of both physical and mental health, including social activity and quality of life than the development of an independent disease. This determines the relevance of the study of the possibilities of using therapeutic and preventive measures not only for the safe correction of menopausal disorders, but also to relief the severity of the symptoms of endometriosis.

Evaluation of efficiency of correction climacteric syndrome in women of perimenopausal period with reproductive disturbances in anamnesis

The article deals with the issues of application of menopausal hormone therapy (MHT) in women of perimenopausal age with menopausal syndrome and reproductive disorders in the anamnesis.46 women with moderate or severe degree of climacteric syndrome and reproductive disorders in the anamnesis (the main group) who received the drug Climonorm on a three-week schedule with a seven-day break were examined. The comparison group consisted of 19 patients of the same age who had contraindications to the use of MHT.In a reproductive history in patients marked loss of pregnancy at different gestational age; PID; operative interventions for benign ovarian tumors, ectopic pregnancy, genital endometriosis, infertility; abnormal uterine bleeding, not associated with pregnancy or the presence of uterine fibroids. During the period of inclusion in the study, 38.5% of women were regular menstrual circle (MC), 15.4% reported intermenstrual bleeding, 18.5% had hyperpolymenorrhea, and 27.6% had acyclical uterine bleeding of varying intensity. Patients showed complaints of hot flashes, night sweats, sleep disturbances, headache, dizziness, emotional lability, depression, fatigue, muscle and joint pain. Before the beginning of therapy, the severity of menopausal syndrome according to MMI was 47.0 ± 6.1 in the main group, in the comparison group – 45.3 ± 6.9.In the case of MC disorders, a pendulum biopsy of the endometrium or hysteroscopy with separate diagnostic scraping of the walls of the cavity and cervix of the uterus was performed.Morphological examination in 67.9% of cases verified endometrium in the stage of proliferation, in 32.1% – simple non-atypical endometrial hyperplasia.After 6 months of treatment, the patients of the main group had a pronounced positive dynamics of climacteric complaints, the average value of MMI after treatment decreased from 47.0 ± 6.1 to 10.2 ± 1.4 points (p &lt;0.001). In a dynamic US examination, the negative dynamics of M-echo indices was not recorded, 86.3% of women with MC disorders before the start of treatment noted regular menstrual bleeding in the interval between the Climonorm doses.MHT with the use of the Climonorm allows to effectively reduce the severity of manifestations of the climacteric syndrome by 80–60%, ensures the regularity and stability of the MC.The appointment of a cyclic combination of MHT with a strong progestogen component (levonorgestrel) has advantages in women with non-atypical hyperplastic processes in the perimenopause, since it prevents recurrence of uterine bleeding with a reduction or complete reduction of menopausal symptoms and no adverse effect on the endometrium.

The genetic background of climacteric symptoms in women during menopause

The subject of the study is the evaluation of the correlation between the polymorphism of candidate genes in the etiology of depression and the occurrence of the symptoms of the climacteric syndrome in women during menopause. The group subjected to the study comprised of 203 women aged between 42-65 years: 71 of them still menstruated (premenopausal group) and 132 at least one year after the last period (postmenopausal group), admitted to the Department of Gynecological Endocrinology at the University of Medical Sciences in Poznan with symptoms of the climacteric syndrome. All the examined women were evaluated according to the degree of severity of the climacteric syndrome symptoms using the Kupperman index and the concentration of FSH, LH hormones, 17&#x03B2;-estradiol, PRL, total testosterone, and DHEAS in peripheral blood serum. Among the candidate genes in the aetiology of depression the following were selected for the research: the serotonergic system receptor genes: 5HTR2A, 5HTR1B, 5HTR2C, TPH1, TPH2, and MAO-A; the genes of noradrenergic and dopaminergic systems (COMT, NET), the genes of the GABAergic (GABRB1) system, a gene of the estrogen receptor (ESR1), and the genes of the enzymes crucial in the methyl cycle (MTHRF, MTR, and MTHFD1). With regards to the correlation between the examined polymorphisms and the occurrence of the symptoms of the climacteric syndrome, the associations analysis indicated a connection between GABRB1.TaqI polymorphism and the occurrence of vertigo in premenopausal women (0.0198; after correction: 0.0497 CC to CA). The correlation was also found regarding the examined polymorphisms and the concentration of the examined hormones in blood serum: TPH1.MaeI polymorphism and the LH concentration in the postmenopausal group (0.004; after correction: 0.014 CC to CA), NET.Eco147I polymorphism, and the 17&#x03B2;-estradiol concentration in the postmenopausal group (0.0208; after correction: 0.048 GG to GA) and HTR2AMspI polymorphism and PRL concentration in all examined women (0.03; after correction: 0.038 TT to CT).

Features of menopausal syndrome treatment in women with endometriosis

Correction of menopausal disorders on the endometriosis background has certain specificity, due to the fact that the menopausal hormone therapy in this group of women is extremely limited because of the possible endometriosis manifestations, which requires the development of new integrated scheme of nonhormonal therapy. Given the major impact of chronic stress in the mechanism of the endometriosis development and menopausal syndrome, authors found it necessary to use the anti-stress therapy for the treatment of this pathology. Authors had developed a treatment regimen without menopausal hormone therapy for women with mild to moderate climacteric syndrome and with history of endometriosis. Noofen was selected like the main drug as a stabilizer cognitive disorders and antihypoxant, as additional drug was used anxiolytic adaptol. 60 women with climacteric syndrome of mild to moderate severity and with history of endometriosis received treatment during the 6 weeks, which were divided into two groups of 30 women: the first group received monotherapy with noofen, women in the second group received the combined therapy that included adaptol and noofen. Evaluation of the clinical status of patients and severity of menopausal disorders was conducted on a Menopause Rating Scale (MRS). The level of anxiety was measured on a Spielberg scale. Changing the assessment of life quality during therapy was determined by questionnaire Freiburg Personality Inventory (FPI). The therapy result showed a significant improvement in the evaluated parameters in patients of both groups. In second group of women already in the first two weeks after complex therapy the improvements were found in comparison with the group receiving monotherapy. Thus, the chosen regimen helps to quickly eliminate the climacteric syndrome in women with endometriosis, improve and stabilize their psychological profile, recover, improve and adapt the quality of life.

Effects of Back Massage Using Craniosacral Therapy and Deep Tissue Massage on Climacteric Syndrome in Women

Effects of Back Massage Using Craniosacral Therapy and Deep Tissue Massage on Climacteric Syndrome in Women

Comparison of the traditional and nontrditional risk factors of heart desease in woman during perimenopause

Aim of the work : to compare the frequency of occurrence and correspondence of the traditional risk factors of the cardiovascular disease to the nontraditional ones in women during perimenopause. Materials and methods : there were examined 115 women with HD of II stage, 1-2 degree and obesity of I-II degree 50±3,5 years old. Depending on menopause status they were divided: 45 women in perimenopause, 50 women in menopause with 3 years period and 20 practically healthy women in perimenopause as a control group. VEGF concentration was determined by the method of immune-enzyme analysis. Results : it was revealed that in the group of women in menopause was observed the reliable increase of the rate of risk factors of cardiovascular events. Combination of obesity, dyslipidemia, hyperglycemia and the high AP complicates the course of perimenipause period in women. The level of VEGF factor had not the reliable influence on indices of the lipid metabolism (general CS, triglycerides, CS LPLD, CS LPVLD) and BMI in women (p >0,05) in perimenopause period but had the influence of hyperglycemia in premenopause and early menopause periods except CS LPHD and BMI increase and also had the influence on the hyperglycemia level in women in perimenopause. Conclusions: it was established that combination of such RF of CVD as obesity and dyslipidemia essentially complicate the clinical manifestations of climacteric syndrome in women in perimenopause that is proved by the high menopause indices. It was established that at combination of hyperglycemia, dyslipidemia, obesity and high VEGF level the risk of CVD on the SCORE scale increases in women in perimenopause. There was demonstrated the reliable influence of VEGF level on the hyperglycemia and CS LPHD indices in menopause (р<0,05), that gives grounds to consider VEGF as an additional nontraditional RF of CVD in these women

Yifuning postpones ovarian aging through antioxidant mechanisms and suppression of the Rb/p53 signal transduction pathway.

Yifuning is a traditional Chinese medicine recipe that has been used for many years in China for its effects on treating climacteric syndrome in women. The present study aimed to demonstrate the effects and underlying molecular mechanism of Yifuning on the ovaries of aging rats. Selected aging rats were administered different doses of Yifuning (1.0or 2.0g/kg by lavage), and after 6weeks the rats were sacrificed. The activit of indicators of oxidative stress in the serum were measured. The expression levels of 8-oxo-2'-deoxyguanosine (8-OHDG) and p53 in the ovaries were examined using immunohistochemistry. The expression levels of the corresponding genes and proteins were detected by reverse transcription‑quantitative polymerase chain reaction and western blotting analyses, respectively. The results indicated that Yifuning significantly prevented ovarian failure, as indicated by improvements in estrous cycling, reproductive organ weights and sex hormone serum levels. Yifuning significantly increased the levels of superoxide dismutase, glutathione peroxidase, catalase and reduced malondialdehyde and hydrogen peroxide levels. Yifuning reduced DNA damage in the ovaries by reducing the expression of 8‑OHDG and p53. Treatment with Yifuning significantly reduced the age‑induced p19, p53, p21 and Rb activity in the ovaries. The present study demonstrates that Yifuning prevents ovarian failure and the mechanism involved is partly associated with antioxidants and suppression of the Rb/p53 signal transduction pathway.

Менопаузальный синдром у женщин с cахарным диабетом

Climacteric syndrome in women with glycemic disorders is known to have several unique features, including earlier onset in women with type 1 diabetes mellitus (usually at the age of 46?48 years). However, diabetes mellitus is not a contraindication for hormone replacement therapy (HRT), though the appropriate age for its introduction should be determined on a case-by-case basis.

Succinate-Based Preparation Alleviates Manifestations of the Climacteric Syndrome in Women

Clinical placebo-controlled study of Enerlit-Clima (bioactive succinate-based food additive) a showed positive effect of the preparation on general clinical and psychoemotional manifestations of the climacteric syndrome. A trend to an increase in estradiol level in early pathological climacteric and normalization of the endometrial status were observed.

Duration of the climacteric syndrome in women treated by hormonal substitution and in controls

This study investigates the duration of symptoms occurring in vegetative climacteric syndrome in women treated by hormonal substitution and in untreated controls. The average duration of the problem in 97 women who refused hormone treatment and served as the control group was 4.5 yr. A mean duration of 5.4 yr was seen in 85 women treated with oral oestrogens, of 6.4 yr in 20 women treated with a combination of oestradiol and prasterone, and of 12.9 yr in 28 women receiving a combination of oestradiol and testosterone. All of these groups were practically identical as regards initiation of therapy, age, and 17 other case-history, sociological and clinical criteria. Although hormonal treatment of the climacteric syndrome can lengthen the duration of the symptoms, this is not necessarily always the case. The type of medication and the dose undoubtedly play an important role in this connection. It has been shown that oestradiol-testosterone combinations can prolong the period during which the symptoms of the climacteric syndrome occur beyond the period that their occurrence may be regarded as physiological.